Ask about this productRelated genes to: RUNDC3B antibody
- Gene:
- RUNDC3B NIH gene
- Name:
- RUN domain containing 3B
- Previous symbol:
- -
- Synonyms:
- RPIP9, RPIB9
- Chromosome:
- 7q21.12
- Locus Type:
- gene with protein product
- Date approved:
- 2007-08-20
- Date modifiied:
- 2014-11-18
Related products to: RUNDC3B antibody
Related articles to: RUNDC3B antibody
- Endothelial cells (ECs) are key structural and functional components of the blood-brain barrier (BBB). Mouse models are frequently used to study EC biology within the BBB, yet the extent to which human and mouse BBB ECs share conserved transcriptomic features remains unclear. Here, we systematically compare transcriptomic profiles of BBB capillary ECs from adult mice and humans. - Source: PubMed
Publication date: 2026/03/12
Miao YuyangWang JianhaoLi WeihanMäe Maarja AndaloussiJeansson MarieMuhl LarsHe Liqun - This study aimed to identify key genes regulating plasma cell (PC) infiltration in kidney renal clear cell carcinoma (KIRC) and construct a novel prognostic model for predicting KIRC. Clear cell renal cell carcinoma is the most common malignant tumor type of the kidney, with an increasing incidence rate and low survival rates in advanced patients. Plasma cells (PCs), as terminally differentiated B cells, produce highly specific antibodies that effectively target and kill tumors through the antibody-dependent cellular cytotoxicity (ADCC) mechanism. Growing evidence has shown that PC infiltration is closely associated with the progression of various malignant tumors, including ccRCC. Therefore, identifying PC infiltration-related biomarkers is of great significance for the prognosis and treatment of ccRCC patients. Machine learning was used to determine PC-related key genes in KIRC patients. A prognostic model termed PC score was developed using TCGA and ArrayExpress data and validated in external cohorts. The molecular background, immune characteristics, and drug sensitivity of the high PC score group were evaluated. Single-cell sequencing was employed to assess the expression of hub genes in KIRC patients. We identified 9 hub genes associated with PC infiltration, including 3 risk genes (ADAM8, KCNN4, and TCIRG1) and 6 protective genes (RAG1, ATPEV1D, CDKL2, RUNDC3B, SLC30A9, and PPARGC1A), and constructed a PC score based on these key genes. Older age, advanced TNM stage, and higher PC score were independent predictors of shorter overall survival. A nomogram model integrating age, stage, and PC score showed significantly higher predictive value than staging alone (P < 0.01). The high PC score group exhibited a higher abundance of immune cells (e.g., activated B cells, activated CD8 + T cells) in the tumor microenvironment. Drug sensitivity analysis revealed that tyrosine kinase inhibitors (e.g., ceritinib, imatinib) potently inhibited cancer cell lines in the high PC score group, while inhibitors like acalabrutinib were effective in the low PC score group. Patients with higher risk scores showed greater sensitivity to ofloxacin and cortivazol (a cortisol hormone). Expression of hub genes in KIRC patients was validated using a local cohort and single-cell sequencing. We identified key genes regulating PC infiltration in KIRC and proposed a predictive model that effectively identifies high-risk KIRC patients. - Source: PubMed
Publication date: 2025/11/11
Sun XintongYang YuchangLiu MingxuNiu ChengtaoCong ZixiangHe WeiNiu Zhihong - Benign prostatic hyperplasia (BPH) is a common issue among older men. Diagnosis of BPH currently relies on imaging tests and assessment of urinary flow rate due to the absence of definitive diagnostic markers. Developing more accurate markers is crucial to improve BPH diagnosis. - Source: PubMed
Publication date: 2024/12/05
Wang YaXuanWang JingLiu JibinZhu HaiXia - This study aimed to investigate the biological functions of miRNAs in hepatobiliary tumors as the focus of targeted therapy research. - Source: PubMed
Zhang Jia-NingWei FengZheng Bin BinTang LiangChen Feng-Yuan - Docetaxel and cabazitaxel-based taxane chemotherapy are critical components in the management of advanced prostate cancer. However, their efficacy is hindered due to presentation with or the development of resistance. Characterizing models of taxane-resistant prostate cancer will lead to creation of strategies to overcome insensitivity. We have previously characterized docetaxel-resistant C4-2B and DU145 cell line derivatives, TaxR and DU145-DTXR, respectively. In the present study, we characterize cabazitaxel-resistant derivative cell lines created from chronic cabazitaxel exposure of TaxR and DU145-DTXR cells, CabR and CTXR, respectively. We show that CabR and CTXR cells are robustly resistant to both taxanes but retain sensitivity to antiandrogens. Both CabR and CTXR cells possess increased expression of ABCB1, which is shown to mediate resistance to treatment. Interestingly, we also present evidence for coordinated overexpression of additional genes present within the gene locus where resides. This locus, known as the ABCB1 amplicon, has been demonstrated to be amplified in multidrug-resistant tumor cells, but little is known regarding its role in prostate cancer. We show that two ABCB1-amplicon genes other than , and , promote cellular viability and treatment resistance in taxane-resistant prostate cancer models. We present evidence that coordinated amplification of ABCB1-amplicon genes is common in a subset of prostate cancer patients. These data together suggest that ABCB1-amplicon activation plays a critical role in taxane resistance. - Source: PubMed
Publication date: 2021/07/29
Lombard Alan PLou WeiArmstrong Cameron MD'Abronzo Leandro SNing ShuEvans Christopher PGao Allen C